Imagion Restarts MagSense Manufacturing Ahead of Planned Cancer Trials
2 min read
9:03am on Monday 14th of September, 2026 AEST ~9am, 14th Sept, 26
Imagion Biosystems has signed nanoComposix to resume GMP-aligned manufacturing of the MagSense nanoparticle core, a move designed to support its FDA-cleared HER2 breast cancer programme without the fixed cost of an in-house facility. The agreement improves manufacturing readiness, but its value, duration and production commitments remain undisclosed.
- Master Service Agreement with nanoComposix
- GMP-aligned pharmaceutical-grade nanoparticle production
- Support for planned HER2 clinical studies
- No disclosed contract value or production volumes
- Future capacity for prostate and ovarian programmes
nanoComposix Agreement Restarts Core Manufacturing
Imagion Biosystems (ASX:IBX) is putting the manufacturing backbone of its MagSense cancer-imaging platform back in place, signing a Master Service Agreement with specialty nanoparticle CDMO nanoComposix. Under the arrangement, Imagion will provide its proprietary synthesis equipment, software and procedures, while nanoComposix manufactures pharmaceutical-grade core particles under Imagion’s direction.
The timing matters because the U.S. Food and Drug Administration has cleared Imagion’s Investigational New Drug application for MagSense in HER2 breast cancer. The company says the manufacturing work is intended to support current product development, potential commercialisation and additional investigational material for its planned clinical programme.
nanoComposix has previously produced the MagSense HER2 imaging agent used in Imagion’s completed Phase 1 study and for the investigational product planned for the pending Phase 1b/2 study. Its manufacturing process will operate under Good Manufacturing Practice controls, which Imagion says are intended to align the material with U.S. FDA product quality requirements.
Outsourced Production Targets Regulatory Readiness
Rather than build and staff its own facility, Imagion says the CDMO model will keep operating costs low by avoiding those fixed investments. The initial task is to establish a robust manufacturing protocol, with attention to product specifications and shelf-life characterisation that could be needed for a future New Drug Application.
That is preparation rather than approval: the announcement does not disclose a commercial manufacturing commitment, an NDA submission or any assurance that MagSense will reach the market. It also leaves the economic terms of the agreement, its duration, manufacturing costs and committed volumes undisclosed.
The same capability could eventually support MagSense research in prostate and ovarian cancer, but Imagion qualifies that expansion by tying it to the availability of funds and the decision to advance those programmes. The immediate test is narrower and more concrete: whether the new protocol can reliably supply material for the planned HER2 studies while meeting the required quality standards.
Bottom Line?
The agreement removes one practical manufacturing hurdle, but the next value-bearing milestones remain protocol validation, clinical progress and funding for the wider platform.
Questions in the middle?
- When will Imagion confirm that the new manufacturing protocol is established and investigational material is available?
- What will the agreement cost, and are there minimum production volumes or other commitments?
- Can the manufacturing platform support the planned HER2 studies without delaying clinical or regulatory milestones?
